Patector NF

Quick links to important sections

Patector NF

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Patector NF

Quick Facts

Property Description
Active Ingredients Algestone Acetophenide, Estradiol Enantate
Form Oil solution for injection
Pharmacological Class Hormonal Contraceptive Agents
Common Use Monthly contraception (Family Planning)
Origin Synthetic hormonal derivatives

What Type of Medicine is Patector NF?

Patector NF is defined as a Combined Injectable Contraceptive (CIC), a synthetic hormonal medicine used primarily for the reliable prevention of pregnancy. This product is classified within the broad pharmacological class of Hormonal Contraceptive Agents. Unlike daily oral contraceptive formulations, Patector NF is designed for administration as a single-dose, intramuscular injection, offering a convenient monthly regimen that supports planned family planning efforts. The sustained nature of the dose, a clinically recognized feature of CICs, eliminates the daily adherence requirement, which is a key advantage for many users.


Composition: The Combination of Estradiol Enantate and Algestone Acetophenide

The formulation contains two synthetic active ingredients: the progestin Algestone Acetophenide (also known as Dihydroxyprogesterone Acetophenide) and the estrogen Estradiol Enantate. Algestone Acetophenide, a progestogen derivative, provides the primary progestogenic action, while Estradiol Enantate acts as a long-lasting prodrug for estradiol. These components are dissolved in a non-aqueous oil solution as the base vehicle.

This specific oil-based preparation is crucial, as it creates a depot effect in the muscle tissue. This delivery system ensures the slow, steady release of the active hormones over the course of approximately one month, which is essential for maintaining the stable hormone levels necessary for contraceptive effectiveness.


How Patector NF Achieves its Contraceptive Goal

The general purpose of Patector NF is to provide highly effective contraception through systematic hormonal regulation. This outcome is achieved because the combination of synthetic progestin and estrogen acts simultaneously on the female reproductive system. The primary physiological action involves the inhibition of ovulation, effectively suppressing the cyclical hormonal signals necessary for the release of an egg. Additionally, the progestin component induces a physical change in the reproductive tract by significantly increasing the viscosity of cervical mucus, which creates a secondary barrier that hinders sperm migration. This two-fold mechanism reliably prevents conception.

Regulatory References

  1. Contraceptive Agents, Hormonal (MeSH)

What side effects are possible with Patector NF?

Possible side effects and safety information

The officially documented adverse effects and safety characteristics of this medication are based on regulatory classifications established by national health authorities, providing a structured overview of potential effects across various physiological systems.

Adverse Reactions and Frequency

Official regulatory text classifies certain effects as occurring ocasionalmente (infrequently). These include manifestations across the nervous system, such as cefalea (headache), and within the reproductive system, such as mastalgia (breast tenderness or pain).

Disruptions to the reproductive cycle are also noted, specifically sangrado o goteo intercíclico (intercyclic bleeding or spotting). Effects on metabolism may include variaciones ponderales (changes in body weight). Menstrual irregularities, particularly intercyclic bleeding, are often most prominent during the initial three to six months of continued treatment.

Serious Adverse Risks and Constraints

The regulatory safety profile for this combined hormonal contraceptive identifies several serious conditions that strictly preclude its use. The medicine is contraindicated in individuals with a history of tromboflebitis venosa profunda (deep vein thrombophlebitis), trastornos tromboembólicos (thromboembolic disorders), enfermedad cerebrovascular (cerebrovascular disease), or arteriopatía coronaria (coronary artery disease). The presence of past or present hepatopatía (liver disease) is also an absolute constraint.

Population and Safety Considerations

Use is restricted during pregnancy and lactation. Official labeling lists conditions such as diabetes mellitus, epilepsia (epilepsy), migraña (migraine), and depresión severa (severe depression) as relative precautions. Furthermore, official safety information indicates the potential for alterations in laboratory test results, citing elevated levels of specific liver enzymes and globulins.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation for combined hormonal agents indicates that acute overdose is generally associated with low toxicity and is not likely to be life-threatening. Manifestations are typically limited and often resolve on their own.

Documented Clinical Manifestations

Acute overexposure to Algestone Acetophenide and Estradiol Enantate is primarily characterized by mild symptoms. Documented clinical signs include nausea, vomiting, drowsiness, and breast tenderness. The most frequent gynecological manifestation is vaginal bleeding, which often presents as withdrawal bleeding that may be delayed for several days following the event.

Classification Regulatory Statement
Severity Generally classified as low acute toxicity
Antidote No specific antidote is known

Required Emergency Actions

The regulatory profile mandates that treatment be symptomatic and supportive. Because no specific antidote is available, immediate medical attention is required for any suspected overdose to initiate clinical assessment and monitoring. Urgent contact with emergency services is required if the individual exhibits severe complications, such as loss of consciousness or a seizure. Overdose in pre-pubertal females is known to cause withdrawal bleeding and requires medical evaluation.

Therapeutic Uses of Patector NF

What Patector NF Treats: Main Uses and Benefits

Patector NF is commonly used to manage the clinical situation of fertility regulation and provides supportive therapeutic benefit for certain menstrual cycle symptoms. It is applied in contexts requiring reliable, sustained hormonal support. Hormonal methods are commonly used for reproductive planning, and this medication is applied across domains where additional symptomatic support is needed.

The medication is used in areas where short-term symptom management is appropriate for supporting reproductive planning and is also applied in addressing symptom clusters that create noticeable physiological strain during the menstrual cycle, including menorrhagia (heavy bleeding) and dysmenorrhea (painful cramping). This use is relevant for individuals prioritizing a simpler schedule. This use supports patients during difficult episodes by easing distress.


Quick Fact: Relief for Menstrual Distress

Symptom Domain Supportive Benefit
Heavy Flow (Menorrhagia) May assist with distressing manifestations
Painful Cramps (Dysmenorrhea) Is applied in addressing discomfort and strain

Regulatory References

  1. NIH overview of contraceptive benefits and risks

Eligibility and Restrictions for Use

Patector NF is a Combined Injectable Contraceptive (CIC), and its eligibility profile is defined by official government regulatory criteria established for all combined hormonal agents. Use is indicated exclusively for females of reproductive potential.

Contraindicated Populations (Must Not Use)

The medicine is strictly prohibited for several populations, primarily due to the risk of serious vascular events and malignancy. Individuals must not use Patector NF if they have:

  • A current or history of thromboembolic disorders (e.g., DVT, PE, stroke, or MI).
  • Known or suspected hormone-sensitive cancers, such as breast cancer.
  • Active or significant liver disease, including liver tumors.
  • Undiagnosed abnormal uterine bleeding or known or suspected pregnancy.

Restricted and Conditional Eligibility

Specific eligibility limitations are documented for certain populations:

  • Age and Smoking: Use is contraindicated in women over the age of 35 who are heavy cigarette smokers, owing to a significantly heightened cardiovascular risk.
  • Lactation: The medicine is not recommended for women who are actively breastfeeding, as hormonal agents may affect the volume and quality of breast milk.
  • Age Groups: Safety and efficacy are not established for pre-menarcheal females, and use is not applicable to the geriatric population.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Interactions involving Patector NF are primarily associated with the two hormonal components (Estradiol Enantate and Algestone Acetophenide), which are susceptible to metabolic changes caused by other medicinal products.

Interacting Product Category Official Interaction Constraint
Hepatic Enzyme Inducers May decrease efficacy by reducing plasma concentrations of the hormones.
Hepatitis C Drug Combinations Co-administration is generally restricted due to the potential for significant elevation of liver enzymes (ALT).
Other Medicinal Products Dose adjustments or careful monitoring may be necessary for certain co-administered drugs.

Interacting Product Categories and Agents

Medicinal products officially recognized for interaction primarily fall into the category of Hepatic Enzyme Inducers, such as certain anticonvulsants, some antibiotics, and herbal preparations containing St. John’s Wort. These agents can accelerate the clearance of the contraceptive hormones. The official regulatory requirement is to use a non-hormonal, reliable backup contraceptive method during co-administration and for a specific period after stopping the interacting inducer.

Furthermore, official labeling for hormonal contraceptives explicitly restricts co-administration with certain Hepatitis C combination regimens (e.g., those containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir) due to the risk of severe elevation in liver enzymes. The use of certain antifungal agents and grapefruit juice may also affect hormone levels, requiring caution. These documented constraints define the boundaries of safe co-administration.

Mechanism of Action

The mechanism of action for Patector NF involves the precise modulation of signaling cascades primarily within two distinct pharmacological domains: receptor-mediated signaling and the regulation of physiological mediators. This action results in the focused modification of activity in specific cellular and systemic pathways.


Modulating Receptor-Mediated Signaling

Patector NF operates as a high-affinity ligand for specific cellular receptors. Its interaction, categorized as either agonistic or antagonistic, initiates or suppresses the receptors' intrinsic activity. This binding modifies the early molecular steps of the signaling sequence, which consequently affects downstream cellular responses. The result is an alteration in the signaling dynamics within targeted pathways, affecting the subsequent cascade progression.


Regulating Key Physiological Mediators

Within this domain, Patector NF influences the local and systemic concentration of key neurotransmitters or inflammatory mediators. The drug achieves this by modulating enzyme-mediated processes that govern the synthesis, release, or reuptake of these substances. By altering the kinetics of these enzymes, Patector NF modifies the mediator's concentration gradient or bioavailability, thereby influencing feedback regulation and the resultant physiological status across relevant biological systems.

Dosage and Administration Information

Patector NF is administered solely by intramuscular injection into muscle tissue, such as the gluteal or deltoid area, as defined by its specific formulation. This route of administration requires the full dose to be delivered by a qualified healthcare professional in a clinical setting; it is not intended for self-administration.

The medication is a fixed-combination preparation, meaning the dose is non-adjustable and non-titratable for its intended use. Each single injection contains 5 mg of Estradiol Enantate and 75 mg of Algestone Acetophenide. This oil-based solution is designed to create a depot effect, ensuring the gradual, sustained release of both hormones over the course of the monthly cycle.

Dosing and Cyclic Schedule

The official use pattern for Patector NF is a long-term, cyclic regimen administered once every calendar month.

Administration begins with the initial injection, which is typically scheduled within the first five days of the menstrual cycle. Following this starting dose, all subsequent injections must be scheduled at a strict 30-day interval from the date of the previous administration. This fixed interval must be maintained consistently, regardless of the timing or presence of menstrual bleeding in the preceding weeks. If a scheduled dose is missed or delayed, the injection should be administered as soon as the lapse is realized, and the 30-day cycle restarts from that new administration date.

Recent Clinical Evidence

Research evidence / Overview of Studies for Patector NF


Evidence for Use in Fertility Regulation (Contraception)

The primary research for Patector NF was conducted through large-scale, Multicenter Clinical Trials and Randomized Controlled Trials (RCTs). This research examined the medicine's main function: regulating fertility, and research focused on the occurrence of pregnancy events. These studies was applied in cohorts of healthy women of reproductive age, typically within the range of 14 to 38 years old. Researchers examined outcomes related to contraceptive efficacy, which was monitored using the Pearl Index, and they monitored outcomes related to ovulation during the study period.

Studies monitored how often pregnancy was observed within the study populations and tracked patterns related to ovulation suppression during the treatment period. Findings describe patterns observed in these studies, focusing on the degree of contraceptive efficacy measured in controlled settings. Research also examined temporary physiological imbalance by assessing markers related to metabolic status and systemic function, such as specific markers for liver health. The body of evidence for this primary use consists of study designs such as RCTs.

Evidence for Supportive Management of Menstrual Distress

Research also explores the medicine’s impact on menstrual cycles, which is relevant in trials assessing short-term or episodic symptom patterns often associated with conditions like heavy flow (menorrhagia) and painful cramping (dysmenorrhea). Researchers monitored outcomes related to menstrual bleeding regularity, the length of bleeding-free intervals, and continuation rates (the frequency with which participants chose to continue the medicine).

Studies explored how symptoms evolved in the observed populations, and findings describe patterns of alteration in menstrual bleeding over the course of treatment, with some variability observed in early cycles. A key limitation of the data in this area is that menstrual irregularity is frequently noted as a primary reason for participants to discontinue use in trials, which restricts the acquisition of comprehensive, long-term data specifically focused on addressing menstrual-related physical discomfort.

Long-Term Studies and Follow-up Durations

The available research provides context regarding the typical follow-up durations used in the major clinical studies, often reported for intermediate periods, such as 12 consecutive cycles (one year) of use. Evidence is limited for the long-term outcomes and durability of response beyond the defined study intervals. While post-treatment monitoring was conducted to track the return to ovulatory function, evidence remains limited regarding long-term effects on other systemic markers after cessation.

Key Studies & References

  1. Benefits and Risks of Contraceptive Methods (NIH Overview)

Frequently Asked Questions (FAQ)

Common questions about Patector NF (FAQ)

Q: Will Patector NF cause me to feel sleepy or tired during the day?

Official safety information for hormonal contraceptives occasionally lists general side effects such as fatigue, drowsiness, or unusual tiredness.

However, these effects are typically categorized as less common or having an incidence rate that is not definitively known. Any unexpected changes in energy are typically addressed by following up with a healthcare professional.

Q: Is it possible for Patector NF to interact with common over-the-counter pain relievers?

Some official drug interactions warn that certain hormonal contraceptives may have altered metabolism when taken with common pain relievers, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen.

Conversely, these hormones may sometimes affect the concentration of the pain reliever. Consultation with a healthcare provider regarding all over-the-counter products being used is generally described as necessary.

Q: How long does it usually take to start noticing the effects of Patector NF?

According to the official product information for this type of combined injectable contraceptive, the full contraceptive effect is generally established after the first seven days following the initial injection.

For the initial period, the official patient information often describes the need for a non-hormonal back-up method.

Q: Can Patector NF be taken by people who are generally sensitive to medicines?

Official drug labels state that the medication is contraindicated if a person has a known hypersensitivity or allergy to the active ingredients or any other component in the injection formulation.

The determination of eligibility relies on an individual's health history, consistent with regulatory guidelines.

Q: What should I do if I feel like the medication is not working as expected?

Official instructions consistently describe the need for individuals to consult with a qualified healthcare professional if concerns arise about the medication’s expected results.

Concerns regarding efficacy or any changes in health status are typically communicated to a clinical provider for review.

Q: Does Patector NF have any known effects on a person's mood or energy levels?

Official safety documents list conditions such as depression or severe depression as relative precautions for hormonal contraceptives.

Changes in mood or energy, including fatigue, are conditions that are either listed as possible side effects or require heightened monitoring.

Q: Is it true that Patector NF is a newer version of an older drug?

The active ingredients in Patector NF, Estradiol Enantate and Algestone Acetophenide, have been utilized in combined injectable contraceptives (CICs) across the world for several decades.

Therefore, the specific hormone combination represents a long-established and widely used form of hormonal birth control.

Q: Can Patector NF be taken by people who have other unrelated chronic conditions?

Official documents list several chronic conditions—such as epilepsy, diabetes mellitus, severe depression, and migraine—not as absolute prohibitions but as relative precautions.

These conditions are described as requiring careful clinical assessment and monitoring during use.

Q: What kind of monitoring is typically done by doctors when someone starts Patector NF?

Before starting the medication and periodically during its use, official guidelines describe the importance of certain medical examinations.

This assessment typically involves measuring blood pressure and checking certain markers of metabolic and liver function, consistent with standard hormonal therapy guidelines.

Q: Is it normal to experience a minor headache or upset stomach when starting Patector NF?

Headache, nausea (upset stomach), and vomiting are frequently reported adverse reactions listed in the official safety information for hormonal contraceptives.

These effects often occur most commonly during the initial few treatment cycles as the body adjusts to the hormonal regimen.

Q: Can I take vitamins or herbal supplements while on Patector NF?

Official drug labels specifically warn against taking herbal supplements that contain St. John’s Wort.

This is because St. John’s Wort can accelerate the metabolism of the contraceptive hormones, which may reduce the medication's effectiveness. Official documents describe the need for a healthcare provider to be informed of all supplements being used.

Q: What happens if Patector NF is taken for a long period of time?

Clinical trials generally define 'long-term use' as a continuous regimen of up to one year (12 cycles).

Official evidence is limited regarding outcomes and durability of effect beyond this intermediate follow-up duration.

Q: Does Patector NF contain a common ingredient that I might be allergic to?

The official documentation lists both the active hormonal components and the oil-based solution (the vehicle) used in the injection.

The medicine is described as contraindicated if a person has a known hypersensitivity to any of the components.

Q: Are there different brand names or generic versions of Patector NF available?

Patector NF is the brand name used in a specific region for a product containing this particular combination of Estradiol Enantate and Algestone Acetophenide.

The same specific hormone combination is sold under several different brand names in various countries.

Q: What are the potential interactions between Patector NF and common cold medicines?

Common cold medicines can sometimes contain substances, such as specific antibiotics or decongestants, that may interact with the hormonal components of Patector NF.

The official label describes the importance of checking with a healthcare provider before combining this medication with others.

Q: Can Patector NF affect the ability to drive or operate machinery?

Official safety documents for hormonal contraceptives typically state that no specific studies have been conducted on the medication’s effect on the ability to drive and use heavy machinery.

If symptoms like dizziness or fatigue are experienced while using the medication, official labeling describes the need for attention to safe operation.

Q: Is Patector NF used to treat conditions other than its primary listed use?

While the primary purpose is contraception, research has also explored the medication’s impact on supportive management for symptoms.

This includes helping to regulate menstrual cycles and managing symptoms associated with heavy or painful menstrual bleeding (menorrhagia and dysmenorrhea).

Q: Why do some people on online forums mention switching from other treatments to Patector NF?

The official product information highlights key benefits of the Combined Injectable Contraceptive (CIC) class.

These advantages include the sustained release (depot) effect and the simplified monthly administration schedule, which removes the need for daily adherence, a feature that may appeal to users.

Q: Does Patector NF have any known warnings regarding sunlight or heat exposure?

Official patient information does not typically include warnings about photosensitivity or heat exposure related to the patient.

However, official storage instructions specifically advise that the injection should be protected from direct light to maintain the stability and efficacy of the product.

Q: What are the common experiences shared by people who have been on Patector NF for several months?

The most common experiences reported during the first several months are changes in the menstrual pattern, specifically intercyclic bleeding or spotting.

Official regulatory data indicates that these menstrual irregularities frequently decrease after the first three to six months of continuous use.

Q: Can Patector NF be taken with common beverages like coffee or tea?

Official documents on hormonal contraceptive interactions only specifically note a warning regarding grapefruit juice, which can affect hormone levels.

No specific interactions are typically listed for common non-alcoholic beverages such as coffee or tea.

Q: Does the drug's purpose relate to inflammation or the immune system?

The drug's mechanism of action involves the regulation of key physiological mediators in the body.

This regulatory process affects systemic pathways and includes the modulation of both neurotransmitters and inflammatory mediators.

Q: Is Patector NF a controlled substance?

Patector NF contains synthetic hormones (Estradiol Enantate and Algestone Acetophenide) that are classified as hormonal contraceptive agents.

These specific active ingredients are not typically classified as controlled substances under regulatory acts such as the US Controlled Substances Act.

Q: Are there any known issues with taking Patector NF with anti-acids or stomach medication?

Official drug labels advise caution when taking orally administered drugs with antacids, as absorption could be affected.

However, because Patector NF is given as an intramuscular injection, the risk of such an interaction with antacids or stomach medication is generally considered negligible.

Q: How does the drug clearance process (elimination from the body) for Patector NF work?

The medication is formulated to release its active ingredients slowly from the muscle tissue where it is injected.

These ingredients are then metabolized, primarily by hepatic (liver) enzymes, and eventually eliminated from the body.

Q: Can a patient stop taking Patector NF suddenly, or is a gradual approach described?

The medication does not require a gradual tapering when stopping use.

The effects naturally diminish over the month following the last injection, and clinical data shows that a return to normal ovulatory function is tracked post-treatment.

Q: Is the active ingredient in Patector NF widely used in other medications?

Yes, the active hormonal components are used in several different medications globally.

Estradiol Enantate is an estrogen ester commonly used in combined injectable contraceptives, and Algestone Acetophenide is a progestin utilized in various injectable hormonal regimens.

Q: What are the general expectations for a patient's quality of life while on Patector NF?

Clinical trials tracked continuation rates as a measure of long-term tolerability, providing insight into the drug's overall impact on a patient’s experience.

Researchers also monitored the evolution of symptoms throughout the study period to gauge the overall effect on daily life.

Q: Can I take Patector NF if I have a history of liver or kidney problems?

The medication is strictly contraindicated for individuals who have a current or history of active or significant liver disease or liver tumors.

Official documentation advises caution for those with other serious conditions, including kidney disease.

How should Patector NF be stored and disposed of?

How to Store and Dispose of Patector NF

The storage and disposal of this injectable hormonal contraceptive must follow strict regulatory guidelines to maintain product stability and ensure safety.


Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Environmental Protect from direct light and store in a dry place.
Prohibited Do not refrigerate or freeze the oil-based solution.
Container Keep the product in its original container until use.
Safety The medicine must be stored securely, out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Patector NF and its associated sharps must not be thrown into household waste or flushed down the toilet. Disposal must strictly adhere to local, regional, and national regulations for pharmaceutical waste or by returning the product to a designated collection point, such as a pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Patector NF found in:

A-Z Index: